JP2005220025A - Oral ingestion composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a composition exhibiting an anti-blood coagulation action, not as a pharmaceutical used under supervision by a medical doctor nor as a food requiring special supervision by the medical doctor. <P>SOLUTION: The composition comprises as essential ingredients both CoQ-10 and Natto-kinase, and is provided in a form such as a soft capsule, a hard capsule, a tablet, a powder or a solution so that it can be readily orally ingested. A deactivation-prevention treatment by coating the surroundings of the Natto-kinase with a coating resistant to gastric acid in the stomach suppresses attenuation of activities of Natto-kinase by the acid in the stomach in the case of oral ingestion. The oral ingestion composition of such a constitution is effectively used for prevention of exacerbation of blood rheology and blood coagulation diseases of persons who ingest it. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

  The present invention relates to an oral ingestion composition having an effect of preventing the deterioration of the disease including prevention of specific diseases that can be used as food materials such as health foods and health supplements, which can be used as food materials to be mixed with foods.

  As a coenzyme of a quinone derivative, ubiquinone of coenzyme Q (denoted as coenzyme Q or CoQ-10) is known. Ubiquinone includes several derivatives having 3 to 11 carbon atoms with respect to the isoprenoid chain in the side chain portion, and the structure with n = 10 is CoQ-10.

  Such CoQ-10 (ubiquinone) is known not only to exhibit biological activity as a coenzyme but also to have an effect of improving enzyme utilization efficiency. In particular, in addition to acting on congested tissue, it is considered to act on biological membrane stabilization and antioxidants. Clinically, pharmacological effects have been recognized in improving symptoms of angina pectoris, heart failure, ischemic heart disease, and muscular dystrophy.

  There are also reports that it is effective for treatment of mild and moderate congestive psychiatric symptoms, prevention of side effects of cancer drugs and psychotropic drugs, and periodontal disease.

  Furthermore, it has been reported that it is effective in improving blood coagulation diseases including vascular abnormalities and blood clots. Non-Patent Document 1 discusses such effects on pig blood. Non-Patent Document 2 discusses blood viscosity, erythrocyte membrane resistance, and erythrocyte deformability.

On the other hand, the enzyme nattokinase obtained by culturing Bacillus subtilis natto has long been used to treat heart disease, fatigue recovery, and beriberi. It has also been found to have a thrombolytic effect. Such a thrombolytic action is said to have a property of enhancing not only a direct action but also a physiological lytic action (indirect action).
“Journal of Cardiovascular Pharmacology”, 1996, 28, p.175-181 “Clinical Pharmacology”, June 1990, Vol. 21, No. 2, p.433-437

  The present inventor has not been a method of drug administration based on prescriptions by doctors, pharmacists, etc., but blood aggregation including blood vessel abnormalities, blood clots, etc. I have been thinking about improving the disease.

  Various drugs based on prescriptions by doctors and the like have been developed and provided to actual medical sites. However, the use of pharmaceuticals is performed as a treatment measure after symptoms or signs of blood coagulation disease are confirmed by a doctor or the like. Therefore, in principle, medication management is performed while confirming the therapeutic effect while confirming safety while confirming the presence or absence of side effects under strict management by a doctor or the like.

  Deterioration of blood rheology such as an increase in blood viscosity, blood agglutination diseases including vascular abnormalities and blood clots, etc., the symptoms are potentially advanced, and the symptoms and signs of symptoms appear to be quite advanced It can be said that it was a stage. Therefore, ideally, it is desirable to take preventive measures before symptoms or signs are confirmed in daily life. For example, by taking a substance with an anti-blood agglutinating action in a safe form that does not cause side effects in daily life, such as vitamins, health foods, health supplements, etc. Ideally, it should be possible to prevent or prevent symptoms from worsening and to improve symptoms.

  An object of the present invention is to provide a composition having an anti-blood aggregating action that can be used for health foods, health supplements and the like that can be taken without requiring administration management by a doctor or the like.

  The present inventor has been able to ingest as health food, health supplement, or food itself, and has been researching and studying what is effective for blood coagulation diseases for many years. Among them, nattokinase and CoQ-10 are It has been confirmed that it is preferable from various viewpoints such as being safe as a food and being stably supplied at a relatively low cost.

  However, when they are taken in combination rather than taking them alone, the mechanism of action is unknown, but the synergistic effect is more than simply adding each anti-blood aggregating property. I found out that

  CoQ-10 is said to exhibit an overall effect of reducing blood viscosity by acting on blood vessel maintenance, improving red blood cell deformability, and stabilizing the red blood cell membrane. In addition, it is considered that fibrinogen and fibrin are involved and aggregated in contact with erythrocytes. Such an effect of CoQ-10 has been confirmed. However, this alone does not make the blood smooth.

  On the other hand, it is known that nattokinase acts on plasminogen activation and fibrin degradation, and acts strongly on platelet aggregation suppression. However, the effect of reducing blood viscosity with nattokinase alone is not sufficient.

  However, when both CoQ-10 and nattokinase were used in combination, blood vessel maintenance and blood component restoration occurred, blood coagulation factors were eliminated, and blood viscosity was significantly reduced. At this stage, the mechanism of such a synergistic effect is not clearly understood, but the present inventor has actually found such a phenomenon and arrived at the present invention.

  That is, the orally ingested composition of the present invention is characterized by having both nattokinase and ubiquinone CoQ-10 as essential components. Nattokinase is characterized by being treated to prevent inactivation of stomach acid. The orally ingested composition is characterized by being formed into an enteric preparation. Such an orally ingested composition contains nattokinase having an activity per g of 12000 FU in a range of 2 mg to 400 mg per ingestion unit. The composition for oral intake contains CoQ-10 in a range of 5 mg to 300 mg per oral intake unit.

  The composition for oral intake having such a configuration can be used for preventing blood rheology deterioration of the person taking the composition for oral intake. Or it can also be used for the prevention of the blood coagulation disease worsening of the ingestor of the ingestion composition.

  In the present specification, FU indicating the activity of nattokinase means a fibrin unit indicating a unit of enzyme activity. This is the standard adopted by Nippon Biological Science Co., Ltd. and Godo Seisei Co., Ltd. for its enzyme products. In such a standard, the UV absorbance at 275 nm of the supernatant after the enzymatic reaction using fibrin as a substrate is measured, and the case where the absorbance increases by 0.01 per minute is defined as 1 unit. It is a standard that defines the unit of enzyme activity from the increase in absorbance measured per minute.

  Blood rheology means blood fluidity and viscoelasticity. In general, it is said that the blood rheology is greatly influenced by blood lipid concentration, erythrocyte deformability, and leukocyte adhesion ability in addition to platelet aggregation ability. Such blood fluidity and viscoelasticity can be recently measured by a commercially available cell fluidity measuring device.

  If an abnormality occurs in these values, blood circulation is sluggish. Furthermore, worsening leads to blood aggregation diseases such as venous thrombosis and cerebral thrombosis. On the other hand, when blood rheology is improved, not only blood images but also serum lipids (neutral fat, serum cholesterol, LDL (low density lipoprotein)) are reduced. Therefore, prevention of deterioration of blood rheology directly means prevention of deterioration of blood fluidity and viscoelasticity. More specifically, prevention of deterioration of blood lipid concentration, erythrocyte deformability, leukocyte adhesion ability, etc. This point can be confirmed by a blood test or the like.

  Blood agglutination disease refers to diseases caused by thrombosis or stenosis in blood vessels such as myocardial infarction, angina pectoris, cerebral thrombosis, cerebral embolism, venous thrombosis, etc., but blood rheology at a preliminary stage prior to such disease Diseases caused by abnormalities may be included. Furthermore, a disease caused by a blood vessel abnormality may be included.

  Moreover, prevention of deterioration means preventing at least the current state from getting worse, and also includes the meaning of prevention. Specifically, it means maintenance and improvement of symptoms. Furthermore, it also means prevention that prevents the onset of symptoms.

  Among the inventions disclosed in the present application, effects obtained by typical ones will be briefly described as follows.

  In the composition of the present invention, since CoQ-10 is contained as an essential component, the effect of improving blood rheology such as blood viscosity, erythrocyte membrane resistance, and erythrocyte deformability is exhibited. Furthermore, since nattokinase is also included as an essential component, the blood rheology is improved by thrombolytic action. By applying a treatment for preventing inactivation of gastric acid to nattokinase, it is possible to suppress a decrease in the action of nattokinase due to gastric acid.

  As described above, the composition according to the present invention has an effect of improving blood rheology in blood vessels based on CoQ-10 and nattokinase contained as essential components, but further includes thrombus, blood abnormality, and myocardial infarction. It shows a synergistic effect on prevention, improvement, prevention of deterioration, etc. of diseases such as blood aggregation.

  Hereinafter, embodiments of the present invention will be described in detail. The composition of the present invention is specified as a health food, as a health supplement, directly as a food, or as a food material containing a food additive, eaten or drunk and taken directly from the mouth. It is a composition that can acquire the effect of preventing (including prevention) the deterioration of the disease. It is not necessary to carry out strict administration control under the control of a doctor like pharmaceuticals, it is safe as a food, and it is intended to be safe and can be taken on a daily basis within the range of protecting the usage method It is a thing.

  As mentioned above, the specific disease includes myocardial infarction, angina pectoris, cerebral thrombus, cerebral embolism, venous thrombosis, etc., thrombosis in blood vessels, diseases caused by vascular stenosis, diseases caused by abnormal blood vessels, and such diseases. This refers to diseases caused by abnormal blood rheology at the preliminary stage before the end.

  The orally ingested composition according to the present invention includes both ubiquinone CoQ-10 and nattokinase as essential components. In particular, for nattokinase, the activity is inactivated by acidity. Therefore, if the inactivation prevention treatment for gastric acid is applied so that the action of nattokinase is not attenuated by gastric acid when ingested, such treatment is not performed. The effect expression of nattokinase is improved. As such a deactivation prevention treatment by gastric acid, a treatment in which nattokinase is coated with an acid-resistant coating and made enteric is excellent.

  CoQ-10 is contained in a range of 5 mg or more and 300 mg or less in terms of 100% purity per oral intake unit. The reason for this being 5 mg or more is that if it is less than 5 mg, the effect of preventing deterioration of the specific disease may not be sufficiently expected. The amount of 300 mg or less is defined from the viewpoint of quantitative taking into consideration the oral intake at the time of average intake, ease of swallowing, etc. including children and the like. That is, when it exceeds 300 mg, the amount increases, and there are cases where it cannot be formulated. This is because it may be preferable to divide into a plurality of preparations. More preferably, it may be prepared so as to be contained in a range of 30 mg or more and 100 mg or less.

  Here, the oral intake unit means 1 tablet, 1 capsule, 1 capsule, 1 capsule, 1 capsule, 1 bag, 1 ampule, 1 vial, 1 bottle, 1 bottle for oral intake. The unit at the time of ingestion etc. shall be said. When ingesting, it may be ingested in the number of units as needed.

  Nattokinase was contained so that the activity per g per ingestion unit was in the range of 2 mg or more and 400 mg or less in a state of 12000 FU units. This is because, when the content of nattokinase is less than 2 mg in a state of 12000 FU / g, the effect of preventing deterioration of the specific disease may not be sufficiently expected. Based on judgment from a quantitative point of view. More preferably, it may be prepared so as to be contained in the range of 10 mg or more and 300 mg or less.

  The content of the above-mentioned nattokinase defines the activity unit of nattokinase to be contained, not merely the amount. Therefore, when 6000 FU / g of nattokinase whose active state is half of 12000 FU / g is used, a content twice as much as 2 mg to 400 mg is required.

  Both CoQ-10 and nattokinase having the above-described structure may be formulated so that the above content is satisfied by obtaining a commercial product in a state where purity or activity is clearly specified.

  As CoQ-10, for example, a fermentation method or a synthesis method can be used. Those produced by fermentation are available from Kaneka Chemical Co., Ltd., Mitsubishi Gas Chemical Co., Ltd., and Asahi Kasei Co., Ltd. A synthetic method is available from Nisshin Pharma Co., Ltd.

  As the nattokinase, nattokinase (Fibrinolytic enzyme) obtained from the culture of Bacillus subtilis natto is used. Such nattokinase can be obtained from Nihon Biological Sciences Co., Ltd. and Godo Sakesei Co., Ltd., each having an active unit of about 12000 FU.

  In addition, as described above, the oral ingestion composition according to the present invention contains CoQ-10 and nattokinase described above as essential components, and may be composed of only both components, or may be formulated. In this case, the necessary excipients, auxiliary agents, or additives, or other mixtures such as any combination of excipients, auxiliary agents, and additives may be mixed.

  The oral ingestion composition according to the present invention may be provided in a powder state, but for example, conventional methods such as soft encapsulation, hard encapsulation, tableting, powdering, and liquid formulation are applied so that it can be easily taken from the mouth. It may be provided in the form. In such a form, if it is made into an enteric preparation, it is effective as a deactivation prevention treatment for the gastric acid of nattokinase contained.

  Moreover, if it is made into soft capsules, hard capsules, tablets, or powders, it can be easily taken from the mouth together with water or tea. If it is configured as a liquid, it can be drunk. Moreover, since the addition amount can be easily adjusted if it is made into a liquid or powder, it can be easily used in the form of a food additive added to other food materials.

  In soft encapsulation, for example, an oral intake composition according to the present invention may be suspended in rice bran oil, soybean oil, or other edible oil, and bead wax or the like may be added to form a gelatin capsule. Or an excipient | filler can be added to the oral ingestion composition which concerns on this invention, and it can also be made into a hard capsule by making into a gelatin hard capsule (two piece capsule).

  Moreover, you may tablet into the state which added the excipient | filler to the oral ingestion composition which concerns on this invention. Alternatively, it may be formed into granules by granulation. Furthermore, it may be converted into a solution by dissolving nattokinase in an emulsion of CoQ-10.

  When provided in the above form, nattokinase is inactivated due to acidity and does not exhibit activity. Therefore, as described above, it is possible to prevent inactivation of gastric acid so that it is not affected by gastric acid. It is preferable to enterize it.

  As the deactivation prevention treatment, for example, after coating nattokinase with pectin, it may be used as a blending raw material for the oral intake composition of the present invention. Or it is good also as a mixing | blending raw material, after carrying out polyethylene coating of nattokinase.

  Alternatively, after coating with shellac, it may be double coated with corn protein and used as a raw material. Or after coating with chitosan, it is good also as a mixing | blending raw material. Or it is good also as a mixing | blending raw material, after coating with polydextrose.

  Further, the raw material may be encapsulated after any of the above methods, and then the entire capsule surface may be coated.

  The orally ingested composition according to the present invention provided in such an embodiment can be used as a health food, a health supplement, a food, or a food material such as a food additive. Of course, you may use as a pharmaceutical under administration management of a doctor, a pharmacist, etc.

  Hereinafter, examples of the ingestion composition based on the above embodiment will be described more specifically.

  In this example, a case will be described in which an oral intake composition containing nattokinase and CoQ-10 as essential components is softly encapsulated to obtain a product. In addition, in a present Example, the case where the inactivation prevention process with respect to a gastric acid is not performed to nattokinase is shown. Further, the following amounts indicate the amount per capsule.

  30 mg of CoQ-10 manufactured by Kaneka Chemical Co., Ltd. and 100 mg of 12000 FU / g Nattokinase manufactured by Godo Sakesei Co., Ltd. are suspended in 200 mg of soybean oil. Further, 5 mg of stearic acid glycerin ester and 10 mg of beeswax are added and emulsified. After emulsification, soft capsules were formed with 116 mg of gelatin, 60 mg of water, and 54 mg of glycerin.

  The capsule size was 6 oval. Thereafter, it was dried to obtain a product. The moisture of the soft encapsulated product after drying was 17 mg. The total weight was about 535 mg. Of these, the average content weight was 345 mg, and the average outer capsule weight was 190 mg.

  Also in this example, a case will be described in which an oral intake composition containing nattokinase and CoQ-10 as essential components is softly encapsulated to obtain a product. In this example as well, nattokinase has not been subjected to a deactivation prevention treatment for gastric acid. The following amounts indicate the amount per capsule.

  60 mg of CoQ-10 manufactured by Nisshin Pharma Co., Ltd. and 100 mg of 12000 FU / g nattokinase manufactured by Nihon Biological Science Co., Ltd. are suspended in 180 mg of rice bran oil. Further, 10 mg of glycerin fatty acid ester and 10 mg of beeswax are added and emulsified. After emulsification, gelatin was softly encapsulated using gelatin 116 mg, water 60 mg, glycerin 54 mg, caramel pigment 1.5 mg, and titanium oxide 1 mg. The capsule size was 6 oval. Thereafter, it was dried to obtain a product. The moisture of the soft encapsulated product after drying was 17 mg. The total weight was about 550 mg. Of these, the average content weight was 360 mg, and the average outer capsule weight was 190 mg.

  In Examples 1 and 2, the case where the inactivation prevention treatment by gastric acid was not performed on the nut-kinase was shown, but in this example, the case where the above-mentioned inactivation prevention treatment was applied and the enterolytic structure was formed is shown.

  100 g of 12000FU / g nattokinase powder manufactured by Godo Sakesei Co., Ltd. is gradually added to 500 ml of an aqueous solution in which 200 g of polydextrose is dissolved, and uniformly dissolved. Then, it dries and creates a powder. The coating was carried out in this way, and after coating, it was pulverized to 80 mesh or more, preferably 120 mesh. The pulverized product thus obtained was used as the nut-kinase of Example 1 and soft-encapsulated under substantially the same conditions. In addition, it is assumed that the actual activity of nattokinase is about 1/3 per weight by coating processing, but when the activity was actually measured, it was confirmed that the expression was about 2000 FU / g when it originally became 4000 FU / g.

  In this example, the deactivation prevention treatment was performed not by directly performing the deactivation prevention treatment on the nattokinase described in Example 3, but by providing a multiple structure on the exterior side containing the nattokinase.

  That is, the product soft-encapsulated in Example 2 was coated with shellac and further coated with corn protein to coat the outer periphery of the soft capsule twice. In such a configuration, the soft capsule inside the double coat is configured to enteric so that it does not disintegrate in the stomach but reaches the intestine and dissolves.

  In this example, a case where soft encapsulation is performed using nattokinase subjected to inactivation prevention treatment will be described. The following amounts indicate the amount per final soft capsule.

  First, 66.6 mg of Nattokinase (12000FU / g) manufactured by Nihon Bioscience Co., Ltd. was dissolved in 133 mg of polydextrose aqueous solution, and then freeze-dried to obtain a powder. This powder was pulverized to 100 mesh. A suspension was prepared by adding 60 mg of pulverized powder, 60 mg of CoQ-10 manufactured by Nisshin Pharma Co., Ltd., 300 ml of rice bran oil, 20 mg of glycerin ester and 20 mg of bees wax, and sufficiently emulsified.

  Thereafter, a soft capsule was prepared with an outer packaging solution of 160 mg of gelatin, 70 mg of glycerin, 80 mg of water, 2.3 mg of caramel pigment, and 1.8 mg of titanium dioxide. The capsule size was 10 oval. After making the capsule, it was dried. The water content was 22 mg. The average content was 600 mg and the total weight was 860 mg.

  In the present embodiment, unlike the first to fourth embodiments, the case of using the ingested composition according to the present invention in a tablet form, rather than encapsulating, will be described. In this example, the deactivation prevention treatment by polydextrose coating is performed. In addition, the following quantity has shown the quantity per tablet.

  That is, 600 mg of the nuttokinase deactivation preventing powder subjected to the deactivation prevention treatment by polydextrose coating of nuttokinase described in Example 3, 60 mg of CoQ-10 manufactured by Kaneka Chemical Industry Co., Ltd. as a shaping material Was mixed with 340 mg of lactose, and then tableted using a tableting means such as a tableting machine. The average weight per tablet was 1 g.

   The reason why the compounding amount of nattokinase was set to the above amount was that the active unit 12000FU / g at the beginning of the compounding was considered to be 2000FU / g, which is about 1/6 of the active unit at the stage of tableting.

  In this example, the case where the oral ingestion composition according to the present invention is powdered and used as a product will be described. In addition, the following quantity has shown the quantity per bag as an oral intake unit.

  That is, 100 mg of CoQ-10 manufactured by Nisshin Pharma Co., Ltd. and 600 mg of nattokinase subjected to an anti-expiration treatment by polydextrose coating, 150 mg of xylitols manufactured by Nikken Chemical Co., Ltd. and 200 mg of lactose were added. Mixed and granulated. The particle size was adjusted to a 30-mesh granule and powdered, and sealed in an aluminum film bag to produce a product. The weight of powder per bag was approximately 1 g.

  In this example, a case where the oral intake composition according to the present invention is used in the form of a liquid is described. The following numerical values are shown as the amount per liquid.

That is, as CoQ-10, Nisshin Pharma Co., Ltd. CoQ-10 10% emulsion was used. To 35 ml of water, 0.3 ml of the above CoQ-10 emulsion and 600 mg of nattokinase subjected to the deactivation prevention treatment prepared in Example 3 were added and dissolved. Furthermore, 2 g of fructose glucose liquid sugar, 1 g of reduced maltose starch syrup, 100 mg of vitamin C, 100 mg of sodium citrate, and 5 mg of vitamin B ₂ were added to add sweetness and aroma. The mixed solution having such a composition was made up to 50 ml with water and put into a bottle with an internal volume of 60 ml for commercialization.

  In this example, the effectiveness of the composition of oral intake of the present invention was verified. In this example, a blood rheology test was conducted using the soft encapsulated oral ingestion composition produced by the method described in Example 3.

  That is, the subject was administered 2 tablets / day daily by oral ingestion, and blood rheology was measured before administration and after 4 weeks. Comparison of blood components before and after administration, and comparison of blood cell (erythrocyte) fluidity were performed. The cell fluidity measurement was performed by measuring the whole blood passage time using MCFAN KH-3 and an artificial capillary model (silicon single crystal substrate). As a result, a reduction effect of the passage time of 30% to 50% with respect to the control was confirmed. In addition, control means the state before administration of the oral ingestion composition of this invention.

  The results of the whole blood passage time are shown in FIGS. 1 (a) shows the results when nattokinase is administered alone, FIG. 1 (b) shows the results when CoQ-10 is administered alone, and FIG. 1 (c) shows the oral ingestion composition of the present invention. The results in the case of administration of are shown respectively.

  In addition, platelet aggregation ability and fibronectin were measured 4 weeks after administration. For the measurement of platelet aggregation ability, a test specimen in which platelet-rich plasma was prepared by mixing at a rate of 9 blood with 1 solution of 130 mM trisodium citrate hydrate (manufactured by Sigma) and centrifuging at 1500 rpm for 3 minutes. Using. This test specimen was subjected to a platelet aggregometer (Chronolog, USA, Chronolog whole blood lumi-aggregometer: model 560-Ca), stimulated with 5 μM ADP to induce aggregation, and the change in transmissivity after 4 minutes. Was measured. As a result, in the case of CoQ-10 alone administration, only a few percent decrease in blood clotting ability was observed, but in the case where the oral ingestion composition of the present invention was administered, blood had a large blood clotting ability of about 20% on average. Decrease was observed. Such a large reduction effect is considered to be a combined effect of CoQ-10 and nattokinase.

  Plasma fibronectin enhances the platelet aggregation ability. This measurement uses EDTA-treated blood, an immune antibody manufactured by Boehringer Mannheim, and an immunosuspension method (turbidometry measurement method). It was measured. As a result, when CoQ-10 was administered alone, the decrease was in the 10% range, but this time, a measurement value as low as approximately 30% was obtained.

  From the above results, it was confirmed that the orally ingested composition according to the present invention clearly has an effect of improving blood rheology such as blood viscosity reduction, erythrocyte membrane resistance and erythrocyte deformability.

  As mentioned above, the invention made by the present inventor has been specifically described based on the embodiment. However, the present invention is not limited to the embodiment, and various modifications can be made without departing from the scope of the invention. Needless to say.

  INDUSTRIAL APPLICABILITY The present invention can be effectively used in the fields of prevention of blood rheology deterioration and prevention of blood agglutination diseases.

(A)-(c) is a figure which shows the result of the whole blood passage time in the test of blood rheology in a tabular form.

Claims (7)

  An orally ingested composition comprising nattokinase and CoQ-10, which is a ubiquinone, as essential components. The orally ingested composition according to claim 1,
The ingestion composition, wherein the nuttokinase is subjected to a deactivation prevention treatment for gastric acid. The orally ingested composition according to claim 1,
The oral intake composition is formed into an enteric preparation. The orally ingested composition according to claim 1,
The oral ingestion composition comprises the nuttokinase having an activity per g of 12000 FU in the range of 2 mg to 400 mg per oral intake unit. The orally ingested composition according to claim 1,
The oral intake composition contains the CoQ-10 in a range of 5 mg to 300 mg per oral intake unit. The orally ingested composition according to claim 1,
The orally ingested composition is used for preventing blood rheology deterioration of a user of the ingested composition. The orally ingested composition according to claim 1,
The oral ingestion composition is used for preventing a blood coagulation disease from being worsened by a person who takes the oral ingestion composition.

Images